Deodorizing preparations

Abstract

PCT No. PCT/EP97/05523 Sec. 371 Date Apr. 16, 1999 Sec. 102(e) Date Apr. 16, 1999 PCT Filed Oct. 8, 1997 PCT Pub. No. WO98/17241 PCT Pub. Date Apr. 30, 1998The invention relates to novel deodorizing preparations with increased synergetic performance containing (a) sterol sulfate, (b1) aluminum chlorhydrate, (b2) esterase inhibitors and/or (b3) bactericidal or bacteriostatic active substances.

We claim: 
     
       1. A deodorizing formulation comprising: (a) a sterol sulfate;   (b) aluminum chlorohydrate; and   (c) an esterase inhibitor, a bactericidal agent, or a bacteriostatic agent.   
     
     
       2. A formulation according to claim 1, wherein the sterol sulfate is a phytosterol sulfate. 
     
     
       3. A formulation according to claim 1, wherein the esterase inhibitor is a trialkyl citrate. 
     
     
       4. A formulation according to claim 1, wherein the bactericidal agent or the bacteriostatic agent is a chitosan. 
     
     
       5. A deodorizing formulation comprising: (a) 0.01% to 50% by weight of a sterol sulfate;   (b) 1.0% to 50% by weight of aluminum chlorohydrate;   (c) 0.01% to 20% by weight of an esterase inhibitor; and   (d) 0.01% to 5% by weight of a bactericidal or bacteriostatic agent, said percents based on the total solids weight of the formulation.   
     
     
       6. A formulation according to claim 5, comprising: (a) 0.1% to 5% by weight of a sterol sulfate;   (b) 10% to 50% by weight of aluminum chlorohydrate;   (c) 1% to 5% by weight of an esterase inhibitor; and   (d) 0.1% to 1% by weight of a bactericidal or bacteriostatic agent.   
     
     
       7. A formulation according to claim 5, wherein the sterol sulfate is derived from a sterol selected from the group consisting of phytosterols, zoosterols, lanosterols, spongosterols, and stellasterols. 
     
     
       8. A formulation according to claim 7, wherein the sterol sulfate is derived from a phytosterol selected from the group consisting of ergosterols, campesterols, stigmasterols, and sitosterols. 
     
     
       9. A formulation according to claim 5, wherein the aluminum chlorohydrate has the formula [Al 2  (OH) 5  Cl].2.5H 2  O. 
     
     
       10. A formulation according to claim 5, wherein the esterase inhibitor is selected from the group consisting of trialkyl citrates, dicarboxylic acids and esters thereof, and hydroxycarboxylic acids and esters thereof. 
     
     
       11. A formulation according to claim 10, wherein the esterase inhibitor is selected from the group consisting of trimethyl citrate, tripropyl citrate, tributyl citrate, triethyl citrate, glutaric acid, glutaric acid monoethyl ester, glutaric acid diethyl ester, adipic acid, adipic acid monoethyl ester, adipic acid diethyl ester, malonic acid, malonic acid diethyl ester, citric acid, malic acid, tartaric acid, and tartaric acid diethyl ester. 
     
     
       12. A formulation according to claim 5, wherein the bactericidal or bacteriostatic agent is selected from the group consisting of chitosan, phenoxyethanol, and chloro-2-(2,4-dichlorophenoxy)-phenol. 
     
     
       13. A deodorizing formulation comprising: (a) 0.01% to 50% by weight of a sterol sulfate;   (b) 1.0% to 50% by weight of aluminum chlorohydrate; and   (c) 0.01% to 20% by weight of an esterase inhibitor or 0.01% to 5% by weight of a bactericidal or bacteriostatic agent, said percents based on the total solids weight of the formulation, wherein the sterol sulfate is derived from a sterol selected from the group consisting of phytosterols, zoosterols, lanosterols, spongosterols, and stellasterols, the aluminum chlorohydrate has the formula [Al 2  (OH) 5  Cl].2.5H 2  O, the esterase inhibitor is selected from the group consisting of trialkyl citrates, dicarboxylic acids and esters thereof, and hydroxycarboxylic acids and esters thereof, and the bactericidal or bacteriostatic agent is selected from the group consisting of chitosan, phenoxyethanol, and chloro-2-(2,4-dichlorophenoxy)-phenol.   
     
     
       14. A formulation according to claim 13, wherein the sterol sulfate is derived from a phytosterol selected from the group consisting of ergosterols, campesterols, stigmasterols, and sitosterols, and the esterase inhibitor is selected from the group consisting of trimethyl citrate, tripropyl citrate, tributyl citrate, triethyl citrate, glutaric acid, glutaric acid monoethyl ester, glutaric acid diethyl ester, adipic acid, adipic acid monoethyl ester, adipic acid diethyl ester, malonic acid, malonic acid diethyl ester, citric acid, malic acid, tartaric acid, and tartaric acid diethyl ester.